Skip to content
BY 4.0 license Open Access Published by De Gruyter (O) February 28, 2020

Crystal structure of 3-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-ylthio)-propanoic acid, C15H17N3O4S

  • Raed A. Al-Qawasmeh EMAIL logo , Yaseen A. Al-Soud , Kafa’ A. S. Alhelal and Monther A. Khanfar ORCID logo

Abstract

C15H17N3O4S, monoclinic, P21/c (no. 14), a = 8.7938(5) Å, b = 10.3071(4) Å, c = 18.0413(7) Å, β = 79.704(5)°, V = 1608.91(13) Å3, Z = 4, Rgt(F) = 0.0535, wRref(F2) = 0.1447, T = 293(2) K.

CCDC no.: 1983007

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Yellow needle
Size:0.20 × 0.08 × 0.04 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.23 mm−1
Diffractometer, scan mode:Xcalibur, ω
θmax, completeness:29.4°, >99%
N(hkl)measured, N(hkl)unique, Rint:13496, 3872, 0.024
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2949
N(param)refined:210
Programs:CrysAlisPRO [1], Olex2 [2], SHELX [3], [4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C20.3431(2)0.5935(2)0.12722(11)0.0415(5)
C40.5704(2)0.57847(18)0.14962(10)0.0347(4)
C50.4858(2)0.49883(17)0.20211(10)0.0346(4)
C60.1992(3)0.4443(3)0.22675(14)0.0572(6)
H6A0.22800.36070.24460.069*
H6B0.12860.42890.19200.069*
C70.1166(3)0.5209(2)0.29258(12)0.0436(5)
C80.0151(3)0.4556(3)0.34764(14)0.0591(7)
H8−0.00160.36710.34300.071*
C9−0.0615(3)0.5232(4)0.40970(17)0.0784(9)
H9−0.13040.47950.44640.094*
C10−0.0372(3)0.6529(4)0.41781(17)0.0754(9)
H10−0.08860.69690.45990.090*
C110.0630(3)0.7177(3)0.36372(16)0.0633(7)
H110.08030.80590.36920.076*
C120.1386(3)0.6525(2)0.30091(13)0.0535(6)
H120.20490.69760.26380.064*
C130.2072(3)0.6336(3)0.09344(15)0.0556(6)
H13A0.11360.62260.13050.067*
H13B0.21670.72490.08030.067*
C140.1942(4)0.5568(4)0.02478(17)0.0802(9)
H14A0.28820.5647−0.01130.120*
H14B0.10930.58900.00320.120*
H14C0.17660.46720.03820.120*
C150.4653(3)0.4775(2)0.35832(10)0.0454(5)
H15A0.35520.49260.36260.055*
H15B0.48010.42130.39960.055*
C160.5440(3)0.6050(2)0.36621(11)0.0457(5)
H16A0.51990.66530.32870.055*
H16B0.65500.59220.35720.055*
C170.4931(3)0.6619(2)0.44351(11)0.0396(4)
N10.3383(2)0.50834(17)0.18600(9)0.0410(4)
N30.4842(2)0.63536(17)0.10350(9)0.0393(4)
N40.7315(2)0.61092(19)0.14151(11)0.0493(5)
O10.7821(2)0.6940(2)0.09657(12)0.0772(6)
O20.8101(3)0.5537(3)0.18006(15)0.1054(9)
O30.3872(2)0.62118(17)0.48889(9)0.0614(5)
O40.5777(2)0.76200(18)0.45648(9)0.0647(5)
H40.54820.78820.49960.097*
S10.53533(9)0.39477(5)0.26997(3)0.0542(2)

Source of material

The title compound was synthesized earlier [5] according to the following procedure. To a solution of 5-bromo-1-benzyl-2-ethyl-4-nitro-1H-imidazole [6] (3.10 g, 10.0 mmol) in iPrOH (50 mL) was added 3-mercapto-propanoic acid (1.06 g, 10.0 mmol) and KOH (0.56 g, 10.0 mmol) and stirred at 60–70 °C for 4 h. After cooling, the solution was neutralized with 1 N HCl to give the title compound (2.0 g, 60%) as a powder. M.p. = 167–170 °C (dec.). MS-FAB m/z : 358 (M + Na)+. 1H-NMR (500 MHz, CDCl3, 298 K): δ [ppm] 10.8 (s, 1H, CO2H); 7.35-7.26 (m, 3H, Ph-H); 6.99-6.95 (m, 2H, Ph-H); 5.35 (s, 2H, PhCH2); 3.15 (t, 2H, J = 6.8 Hz, SCH2CH2); 2.66 (t, 2H, J = 6.8 Hz, SCH2CH2); 2.58 (q, 2H, J = 6.8 Hz, CH2CH3); 1.26 (t, 3H, J = 6.8 Hz, CH2CH3). 13C-NMR (125 MHz, CDCl3, 298K): δ [ppm] 174.8 (CO2H); 150.7 (C-2); 134.9 (C-4); 129.3, 129.2, 128.4, 126.0, 125.7 (C-5, Ph-C); 48.6 (CH2Ph); 34.1 (SCH2CH2CO2H); 31.2 (SCH2CH2CO2H); 21.3 (CH2CH3); 11.6 (CH2CH3). Anal. Calcd for C15H17N3O4S (335.38): C, 53.72; H, 5.11; N, 12.53. Found: C, 53.43; H, 5.00; N, 12.31.

Experimental details

Melting points were measured on a B-545 (Büchi Labortechnik AG, Switzerland) and are uncorrected. Microanalytical data were obtained with a Vario, Elementar apparatus (Shimadzu, Japan). NMR spectra were recorded on 300 MHz (1H) and at 150.91 MHz (13C) spectrometers (Bruker) with TMS as standard. The following abbreviations are used to describe peak patterns: s = singlet, t = triplet, q = quartet, m = multiplet, bs = broad singlet. The 1H and 13C-NMR chemical shift assignments are supported by data obtained from heteronuclear 1H-13C HMQC and 1H-13C HMBC. Mass spectra were recorded on EI and FAB MAT 8200 spectrometers (Finnigana MAT), using 3-nitrobenzyl alcohol (NBOH) or glycerol as matrixes. Molecular ions were detected by doping the sample with Na+ ion.

Single crystals of C15H17N3O4S were crystallized from CHCl3/Et2O. Using Olex2 [2], the structure was solved with the ShelXT [3] using Intrinsic Phasing and refined with the ShelXL [4] refinement package. All H atoms were refined as riding.

Comment

Imidazole is an important heterocyclic compound in the aromatic world of medicinal chemistry. It is also an important constituent of several natural products including purine, histidine and nucleic acid. The nitroimidazoles have shown great promise for targeting different types of cancers [6], [7]. 5-Halogeno-4-nitro-1H-imidazoles, as the most interesting class of these compounds, showed biological activity as antiparasitic agents [8] and imaging agents [9]. In view of the interest in the activity spectrum and profile of the nitroimidazoles and in continuation of our research on the synthesis and biological evaluation of imidazole analogs [10], [11] we here present the imidazolyl containing title structure.

Herein, the 3-mercapto-propanoic acid was coupled with imidazole ring to produce the target compound. This title crystal structure consists of the C15H17N3O4S molecule, in which all bond lengths are in normal ranges. The asymmetric unit contains the 3-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-ylthio)-propanoic acid. The crystal is stabilized via NH⋯O hydrogen bonds forming a chain along the crystallographic c axis. [O4⋯N3′ = 2.837 Å; ′ = x, 1.5 − y, 0.5 + z].

Acknowledgements

Authors wish to thank the Scientific Research Support Fund/Ministry of Higher Education, Jordan (grant No. Bas 1/1/2017) for providing necessary facilities and funds for conducting this research.

References

1. Rigaku Oxford Diffraction: CrysAlisPRO. Rigaku Oxford Diffraction, Yarnton, England (2015).Search in Google Scholar

2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement & analysis program. J. Appl. Crystallogr. 42 (2009) 339–341.10.1107/S0021889808042726Search in Google Scholar

3. Sheldrick, G. M.: SHELXT – Integrated space-group and crystal-structure determination. Acta Crystallogr. A71 (2015) 3–8.10.1107/S2053273314026370Search in Google Scholar PubMed PubMed Central

4. Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Search in Google Scholar PubMed PubMed Central

5. Al-Soud, Y. A.; Al-Masoudi, N. A.; De Clercqc, E.; Pannecouquec, C.: Nitroimidazoles part 4. synthesis and anti-HIV activity of new 5-alkylsulfanyl and 5-(4′-arylsulphonyl) piperazine 4-nitroimidazole derivatives. Heteroat. Chem. 18 (2007) 333–340.10.1002/hc.20301Search in Google Scholar

6. Al-Masoudi, N. A.; Al-Soud, Y. A.; Kalogerakisa, A.; Pannecouquec, C.; De Clercqc, E.: Nitroimidazoles part 2. synthesis, antiviral and antitumor activity of new 4-nitroimidazoles. Chem. Biodiv. 3 (2006) 515–526.10.1002/cbdv.200690055Search in Google Scholar PubMed

7. Makawana, J. A.; Sangani, C. B.; Lin, L.; Zhu, H.-L.: Schiff’s base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 24 (2014) 1734–1736.10.1016/j.bmcl.2014.02.041Search in Google Scholar PubMed

8. Jarrad, A. M.; Debnath, A.; Miyamoto, Y.; Hansford, K. A.; Pelingon, R.; Butler, M. S.; Bains, T.; Karoli, T.; Blaskovich, M. A. T.; Eckmann, L.; Cooper, M. A.: Nitroimidazole carboxamides as antiparasitic agents targeting giardia lamblia, entamoeba histolytica and trichomonas vaginalis. Eur. J. Med. Chem. 120 (2016) 353–362.10.1016/j.ejmech.2016.04.064Search in Google Scholar PubMed PubMed Central

9. Saini, N.; Varshney, R.; Tiwari, A. K.; Kaul, A.; Isharb, M. P. S.; Mishra, A. K.: Design, synthesis and biological evaluation of coumarin coupled nitroimidazoles as potential imaging agents. RSC Adv. 5 (2015) 97102–97112.10.1039/C5RA17907FSearch in Google Scholar

10. Al-Soud, Y. A.; Al-Sa’doni, H.; Amajaour, H. A. S.; Al-Masoudi, N. A.: Nitroimidazole part 3. synthesis and anti-HIV activity of new N-alkyl 4-nitroimidazoles, bearing benzothiazole and benzoxazole backbones. Z. Naturforsch, B: Chem. Sci. B62 (2007) 523–528.10.1515/znb-2007-0406Search in Google Scholar

11. Al-Soud, Y. A.; Al-Masoudi, N. A.; Al-Suod, H. H.; Pannecouque, C.: Nitroimidazoles part 8. synthesis and anti-HIV activity of new 4-nitroimidazole derivatives using the Suzuki cross-coupling reaction. Z. Naturforsch, B: Chem. Sci. B67 (2012) 925–934.10.5560/znb.2012-0185Search in Google Scholar

Received: 2020-01-02
Accepted: 2020-02-10
Published Online: 2020-02-28
Published in Print: 2020-04-28

©2020 Raed A. Al-Qawasmeh et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Downloaded on 30.5.2024 from https://www.degruyter.com/document/doi/10.1515/ncrs-2020-0003/html
Scroll to top button